Nektar Considers New Phase III Designs For NKTR-181 After Phase II Failure
This article was originally published in The Pink Sheet Daily
Mu-opioid analgesic NKTR-181 fails primary endpoint in Phase II study due to response in placebo arm. Undeterred, Nektar says it will be moving the drug to Phase III and plans to talk to FDA about alternative options for trial design.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.